Raymond James analyst Steven Seedhouse upgraded Madrigal Pharmaceuticals to Market Perform from Underperform.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on MDGL:
- Madrigal Pharmaceuticals price target raised to $194 from $75 at B. Riley
- Madrigal’s data bodes well for Viking’s de-risked VK2809, says BTIG
- Akero’s efruxifermin efficacy still compares favorably, says Morgan Stanley
- Trial success is rocketing this NASH stock higher and sinking these peers
- Madrigal Pharmaceuticals price target raised to $280 from $203 at Piper Sandler